Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QseC inhibitor
- Development stage
- Preclinical
- Lead developer
- OMM Scientific
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QseC inhibitor is a small molecule anti-virulence agent being developed by OMM Scientific for the treatment of Gram-negative bacterial infections. The drug targets the QseC (Quorum-sensing Escherichia coli regulator C) receptor, a membrane-bound histidine kinase that acts as a sensor for host stress hormones (epinephrine and norepinephrine) and bacterial signaling molecules (autoinducer-3). By antagonizing QseC, the compound prevents the activation of virulence genes that allow pathogens like *Escherichia coli*, *Salmonella*, and *Francisella tularensis* to cause disease. This approach is non-bactericidal, meaning it does not kill the bacteria or inhibit their growth, which is intended to reduce the selective pressure for antibiotic resistance. The program is based on the research of OMM Scientific's co-founder, Dr. Vanessa Sperandio, and includes the lead candidate LED209.
- Other names
- QseC antagonistQseC receptor antagonistQseC inhibitorsQseC antagonists
02
Targets
QseC (Sensor histidine kinase QseC)
Beyond the preview
Go deeper on QseC inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QseC inhibitor.